Krajonon - instructions for use, analogs, reviews and release forms (gel vaginal) drugs for the treatment of female infertility, artificial insemination or IVF, bleeding and menopause in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Krainon. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of experts on the use of Krajonon in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Krainon in the presence of existing structural analogs.The use for the treatment of female infertility, in vitro fertilization, or IVF, with bleeding and menopause in adults, children, and during pregnancy and breastfeeding. Composition of the preparation.

Krainon - gestagen. Progesterone (the active ingredient of the drug Krajonon) is the hormone of the yellow body. Causes the transition of the mucous membrane of the uterus from the proliferation phase, caused by the action of FSH, into the secretory phase. Reduces excitability and contractility of the musculature of the uterus and fallopian tubes.

Progesterone inhibits the secretion of hypothalamic releasing factors, FSH and LH, inhibits the formation of the pituitary gonadotropins and inhibits ovulation.

In preparation Kraynon progesterone vaginal gel incorporated into the polymer delivery system that is associated with the vaginal mucosa and provides sustained release of progesterone, at least 3 days.

Composition

Progesterone + auxiliary substances.

Pharmacokinetics

When a vaginal gel is used in a dose containing 90 mg of progesterone, the Cmax of the active substance in the blood is reached after 6 hours and is 11 mg / ml. Progesterone is metabolized predominantly in the liver.Intravaginal application significantly reduces the effect of "first passage" through the liver. The main metabolite, 3-alpha, 5-beta-pregnanediol, is excreted in the urine.

Indications

• maintenance of the luteal phase in the process of using assisted reproduction methods (with IVF);
• secondary amenorrhea (absence of menstruation), dysfunctional uterine bleeding due to progesterone deficiency;
• replacement hormone therapy in postmenopause (in combination with estrogenic drugs).

Forms of release

Gel vaginal white (sometimes mistakenly called ointment or cream).

Other dosage forms, be it tablets, capsules or candles, do not exist.

Instructions for use and how to use them

Maintenance of the luteal phase in the use of assisted methods of reproduction

Starting from the day of embryo transfer, the gel is used in a dose of 1.125 g (90 mg of progesterone - 1 applicator) and administered daily intravaginally. At the onset of pregnancy, therapy is continued up to 12 weeks or for 10-12 weeks from the date of confirmed pregnancy.

Secondary amenorrhea, dysfunctional uterine bleeding due to progesterone deficiency

1.125 g of gel (90 mg of progesterone) is administered intravaginally every other day from the 15th day to the 25th day of the cycle. If necessary, the dose may be decreased or increased.

Replacement hormone therapy in postmenopause (in combination with estrogen preparations)

90 mg (1 applicator) is administered 2 times a week.

Terms of use

It is necessary to inform the patient about the need to strictly follow the recommendations for the use of the drug.

To comply with hygienic conditions and ease of use, Krainon is packaged in a disposable applicator, which should be discarded after use.

1. Take the applicator by tightly holding it in the upper part between the thumb and forefinger. Shake the applicator like a medical thermometer so that the gel moves to the lower end of the applicator.

2. Hold the applicator behind the upper flat end of the air container. Remove the detachable cap from the opposite end by turning. Do not apply pressure to the air container.

3. The applicator can be inserted both in the sitting position and in the prone position with slightly bent knees. Carefully insert the lower end of the applicator into the vagina.

4.Strongly squeeze the air container so that the gel from the applicator gets into the vagina. Despite the fact that some amount of gel remains in the applicator, the dose is completely introduced. Now the applicator with the remaining gel can be discarded. Krajnon covers the vaginal mucosa, ensuring a prolonged release of progesterone.

Side effect

• headache;
• drowsiness;
• stomach ache;
• tenderness of the mammary glands;
• intermenstrual bleeding;
• irritation of the mucous membrane of the vagina and other local moderate reactions in the field of application;
• hypersensitivity reactions are possible, usually manifested as a skin rash.

Contraindications

• vaginal bleeding of unclear etiology;
• acute porphyria;
• malignant tumors of genital organs or mammary glands, or suspected of their presence;
• acute thrombosis or thrombophlebitis, thromboembolic disease;
• acute disturbance of cerebral circulation (including in the anamnesis);
• incomplete abortion;
• the period of breastfeeding;
• hypersensitivity to the components of the drug.

Application in pregnancy and lactation

Kraynon can be used in the first trimester of pregnancy if the function of the yellow body is insufficient. The use of the drug Krainon in later terms of pregnancy is not recommended.

Contraindicated in the period of breastfeeding.

Use in children

Not noted.

special instructions

Special attention should be paid to the possible appearance of early symptoms of thrombotic disorders (thrombophlebitis, cerebral circulation disorders, pulmonary embolism and retinal thrombosis). If a symptom is found that indicates these disorders, or even suggests that they are present, the drug should be immediately withdrawn.

Patients with any risk factors for thrombotic disorders should be closely monitored.

In the process of long-term treatment, regular gynecological examinations are necessary in order to exclude the possibility of developing endometrial hyperplasia.

A physical examination before the start of therapy should include an assessment of the condition and development of the mammary glands and pelvic organs, as well as a cervical smear (Papanicolaou test).

In order to prevent the possibility of incomplete abortion with the use of the drug Krainon, it is necessary to determine the level of chorionic gonadotropin or to perform ultrasound.

Use with caution in case of liver dysfunction, with arterial hypertension, chronic renal failure, cardiovascular insufficiency, diabetes mellitus, bronchial asthma, epilepsy, migraine, depression, hyperlipoproteinemia.

In cases of bleeding, such as in all cases of irregular vaginal bleeding, organic pathology should be ruled out.

In the case of vaginal bleeding of unclear etiology, an appropriate examination should be carried out.

Because progestogens have the ability to retain fluid in the body, patients with diseases such as epilepsy, migraine, bronchial asthma, cardiovascular failure, impaired renal function, should be closely monitored.

It is necessary to closely monitor patients who have a history of depression and interrupt treatment if depression worsens.

A small number of patients receiving estrogen-progestagen therapy may experience a decrease in glucose tolerance. The mechanism of this violation is not known. In this regard, patients with diabetes mellitus should be carefully monitored during progesterone treatment.

The drug Krainon is sorbic acid, which can cause a local skin reaction (contact dermatitis).

Effect of the drug on the ability to drive and control other vehicles

Krajonon has a weak or moderate effect on the ability to drive and work with machinery. Because When using the drug Krajnon, you may feel tired or sleepy, you need to be careful when driving a car and other mechanisms. The use of alcohol can enhance this effect.

Drug Interactions

The use of Kraynon along with other intravaginal drugs is not recommended.

The use of alcohol can increase the side effects of the drug.

Analogues of the drug Krainon

Structural analogs for the active substance:

• Iprozhin;
• Prajisan;
• Progesterone;
• Projest;
• Utrozhestan.

Analogues on the pharmacological group (estrogens, gestagens and their homologs and antagonists):

• Aromeston;
• Veldedien;
• Veraplex;
• Byzanne;
• Gestodene;
• Ginepristone;
• Gynestrel;
• Desogestrel;
• Depot Provera;
• The Divigel;
• Duphaston;
• Wife;
• Implanon;
• Iprozhin;
• Climadinone;
• Climara;
• Clomiphene;
• Clostilbite;
• Lactineth;
• Levonorgestrel;
• Loveston;
• Medroxyprogesterone;
• Microlus;
• Microfolline;
• Mirell;
• Mirena;
• Miropristone;
• Mifegin;
• Mifepristone;
• Norkolut;
• Norplant;
• Ovestin;
• Organometr;
• Pencrofton;
• Postinor;
• Prajisan;
• Premarin;
• Provera;
• Progesterone;
• Proginova;
• Projest;
• Sinestrol;
• Tamoxifen;
• Utrozhestan;
• Phosphastrol;
• Tzimycycle;
• Charozette;
• Exemestane;
• Exluent;
• Escapel;
• Esmia;
• Estriol;
• Estrovagin;
• Estrogele;
• Estrofem;
• Ethinyl estradiol.

Similar medicines:

Other medicines: